CDI launches iCell® Endothelial Cell Grant Program. Submit your proposal by Jun 8 for a chance to win. Learn More...
iCell Neurons: These human iPS cell-derived brain cells, are now available for your research needs. Learn more...
CDI’s iCell Cardiomyocytes were discussed during a recent American Journal of Physiology podcast. Authors describe published research detailing the electrophysiological characterization of iCell Cardiomyocytes.
The Power of iPS Cell Technology: Any cell type. Any genetic background. Any quantity. These cells deliver. Read more...
With 100+ employees and >390 patents, CDI manufactures human iPS cell-derived cell types with the quality, quantity, and purity required for basic life science and drug discovery research. Read more...
Apr 15, 2012
Genetic Engineering &
Biotechnology News
Human iPSC-Derived Cardiomyocytes
Apr 2012
Fast Company:
Top 10 Biotech
Apr 3, 2012
Wisconsin State Journal:
Madison Researchers Making Major Breakthroughs in Stem Cell Work
Mar 26, 2012
BioCentury:
iPS Predicting Toxicity
Mar 2012
Investigative Ophthalmology
& Visual Science:
Blood-derived Human iPS Cells Generate Optic Vesicle-like Structures with the Capacity to Form Retinal Laminae and Develop Synapses
iCell® Products |
|
|
iCell Cardiomyocytes |
|
iCell Endothelial Cells |
|
iCell Neurons |
|
iCell Hepatocytes (Coming 2012) |
Have a unique genotype? Ask about our custom iPS cell reprogramming and terminal cell differentiation products and services.
